For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions…
더 읽어보기
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein…
더 읽어보기
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new…
더 읽어보기
The LA Times recently published a fairly negative appraisal of the construct of preclinical Alzheimer’s disease (AD). The article described the recent effort by an international committee to update diagnostic…
더 읽어보기
Black people know intrinsically about the myriad of life areas negatively impacted by the fact that the myth of white supremacy is baked into the foundations of all American institutions.…
더 읽어보기
UCI MIND faculty member and professor in the School of Public Health, Karen D. Lincoln, PhD, MSW, MA, FGSA, is featured in Authority Magazine as being one of the top inspirational…
더 읽어보기
Message from the Director Dear Friends of UCI MIND, Advances in the field of Alzheimer’s disease (AD) research and the contributions of UCI MIND investigators remain tremendously exciting. Two new…
더 읽어보기
The topline results for the Anti-Amyloid treatment in Asymptomatic Alzheimer’s disease (A4) study were released today (https://a4study.org). Unfortunately, the drug being investigated, solanezumab, failed to demonstrate a benefit in slowing…
더 읽어보기
On February 17, 2023, a bipartisan group of Senators sent the Secretary of Health and Human Services, Javier Baccera, and the Administrator of the Centers for Medicare and Medicaid Services…
더 읽어보기
Frontotemporal dementia (FTD) is a form of dementia that typically affects individuals in their 50s and 60s. It is therefore, commonly referred to as young onset dementia. Clinically, FTD can…
더 읽어보기